The Diagnostic Value of Gene Expression of FHL1 in the Differential Diagnosis of Papillary Thyroid Carcinoma and Benign Tumors

Document Type : Original Article (s)

Authors

1 Assistant professor, Department of Medical Genetics, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

2 Department of Clinical Biochemistry, Cancer Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

3 Department of Biochemistry, Noor Medical Genetics Laboratory, Ahvaz, Iran

4 Associate Professor, Department of Ear, Nose and Throat, School of Medicine, Ahvaz jundishapur University of Medical Sciences, Ahvaz, Iran

5 Assistant Professor, Department of Pathology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

6 Associate Professor, Department of Pathology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Abstract

Background: Fine needle aspiration (FNA) is the best method for diagnosis of thyroid tumors before surgery and is performed widely for patients; but in about 20% of cases, the test answer is reported as suspicious or intermediate. The aim of this study was to evaluate the mRNA expression of gene FHL1 as a tumor marker in differentiating benign and malignant tumors of papillary thyroid carcinoma.Methods: 50 patients from Ahvaz hospitals (Iran) with malignant (25 cases) and benign (25 cases) thyroid tumors were enrolled in this study. RNA was extracted from paraffin samples with specific kit and the kit was used for cDNA synthesis. Real time polymerase chain reaction (PCR) were consisted of 20 micro liters of the reaction mixture containing the fluorescent Cyber Green.Findings: The relative mRNA expression of FHL1 gene in the malignant group (0.05%) was significantly lower than that in the benign group (5.29%) (P = 0.019). Receiver operating characteristic (ROC) analysis showed that the gene has a good performance for differentiation between benign and malignant thyroid tumors, with area under the curve (AUC) of 0.92. Sensitivity and specificity of FHL1 gene expression as a diagnostic test were 84% and 84%, respectively,Conclusion: Gene expression of FHL1 is more efficient to differentiate papillary thyroid carcinoma from benign tumors.

Keywords

References

  1. McCabe CJ. Novel molecular markers in thyroid cancer. Endocrine Abstracts 2005; 10: S7.
  2. Schagdarsurengin U, Gimm O, Dralle H, Hoang-Vu C, Dammann R. CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. Thyroid 2006; 16(7): 633-42.
  3. Weber F, Shen L, Aldred MA, Morrison CD, Frilling A, Saji M, et al. Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. J Clin Endocrinol Metab 2005; 90(5): 2512-21.
  4. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007; 110(1): 38-46.
  5. Shibru D, Hwang J, Khanafshar E, Duh QY, Clark OH, Kebebew E. Does the 3-gene diagnostic assay accurately distinguish benign from malignant thyroid neoplasms? Cancer 2008; 113(5): 930-5.
  6. Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A. Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms. Surgery 2005; 138(6): 1102-9.
  7. Hoque MO, Rosenbaum E, Westra WH, Xing M, Ladenson P, Zeiger MA, et al. Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J Clin Endocrinol Metab 2005; 90(7): 4011-8.
  8. Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, Lee SH, et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf) 2006; 65(5): 660-6.
  9. Rowe LR, Bentz BG, Bentz JS. Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal 2006; 3: 10.
  10. Asa SL. The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid. Endocr Pathol 2005; 16(4): 295-309.
  11. Cerutti JM, Delcelo R, Amadei MJ, Nakabashi C, Maciel RM, Peterson B, et al. A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin Invest 2004; 113(8): 1234-42.
  12. Ding L, Wang Z, Yan J, Yang X, Liu A, Qiu W, et al. Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-beta-like signaling pathway. J Clin Invest 2009; 119(2): 349-61.
  13. Song Q, Wang D, Lou Y, Li C, Fang C, He X, et al. Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China. Diagn Pathol 2011; 6: 126.
  14. Nikiforov YE: Molecular analysis of thyroid tumors. Mod Pathol Suppl 2011; 2: 34-43.
  15. Fryknas M, Wickenberg-Bolin U, Goransson H, Gustafsson MG, Foukakis T, Lee JJ, et al. Molecular markers for discrimination of benign and malignant follicular thyroid tumors. Tumour Biol 2006; 27(4): 211-20.
  16. Li X, Jia Z, Shen Y, Ichikawa H, Jarvik J, Nagele RG, et al. Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate. Cancer Sci 2008; 99(7): 1326-33.
  17. Sakashita K, Mimori K, Tanaka F, Kamohara Y, Inoue H, Sawada T, et al. Clinical significance of loss of Fhl1 expression in human gastric cancer. Ann Surg Oncol 2008; 15(8): 2293-300.
  18. Shen Y, Jia Z, Nagele RG, Ichikawa H, Goldberg GS. SRC uses Cas to suppress Fhl1 in order to promote nonanchored growth and migration of tumor cells. Cancer Res 2006; 66(3): 1543-52.
Journal of Isfahan Medical School
Volume 31, Issue 266 - Serial Number 266
November and December 2014
Pages 2113-2121

Files

History

  • Receive Date: 27 June 2013
  • Revise Date: 29 April 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics